Assessment of clinical immunogenicity of inotuzumab ozogamicin in patients with non-Hodgkin lymphoma and acute lymphoblastic leukemia

Assessment of clinical immunogenicity of inotuzumab ozogamicin in patients with non-Hodgkin lymphoma and acute lymphoblastic leukemia

Abstract Introduction Inotuzumab ozogamicin (InO) is an antibody-drug conjugate composed of a recombinant, humanized immunoglobulin type G, subtype 4 (IgG4) antibody covalently bound to a semisynthetic derivative of calicheamicin via an acid-labile linker. It was developed for the treatment of relap...

Full description

Bibliographic Details
Main Authors: Darshana Jani, John Nowak, Ying Chen, Joseph Boni, Boris Gorovits
Format: Article
Language:English
Published: SpringerOpen 2018-02-01
Series:AAPS Open
Subjects:
Anti-drug antibody
Immunogenicity
Neutralizing antibody
Inotuzumab ozogamicin (InO)
Pharmacokinetics
Calicheamicin
Online Access:http://link.springer.com/article/10.1186/s41120-018-0021-5

Internet

http://link.springer.com/article/10.1186/s41120-018-0021-5

Similar Items